Mycoplasma genitalium as a sexually transmitted infection: implications for screening, testing, and treatment
- 1Whittall Street Clinic, Birmingham B4 6DH, UK
- 2Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark
- Correspondence to: Professor J Ross Whittall Street Clinic, Whittall Street, Birmingham B4 6DH, UK;
- Accepted 23 March 2006
The evidence that Mycoplasma genitalium is a sexually transmitted pathogen is virtually incontrovertible based on both the concordance rates among partners and on DNA typing showing the same sequence type among partners in contrast to unrelated M genitalium positive patients. The implications that this has for the screening, testing, and treatment of patients is less certain however. Which tests are the most sensitive and specific, what samples are most appropriate, who should be tested, what treatment is best and how should partners be managed?
- NAATs, nucleic acid amplification tests
- NGU, non-gonococcal urethritis
- PMNLs, polymorphonuclear leucocytes
- STI, sexually transmitted infections
JR and JJ jointly wrote and revised the manuscript.
Declaration of interests: JR has received consultancy fees from Bayer and Pfizer and is an associate editor of Sexually Transmitted Infections.